Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
temozolomide + bevacizumab + irinotecan
- Development stage
- Phase 2
- Lead developer
- Duke University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
temozolomide + bevacizumab + irinotecan is an investigational combination chemotherapy and anti-angiogenic regimen. It consists of three active agents: temozolomide (an oral small-molecule DNA alkylating agent), bevacizumab (a recombinant humanized monoclonal antibody targeting VEGF-A to block angiogenesis), and irinotecan (a small-molecule topoisomerase I inhibitor prodrug). This combination has been evaluated in clinical trials for various aggressive malignancies, including newly diagnosed and recurrent glioblastoma, relapsed or refractory high-risk neuroblastoma, and desmoplastic small round cell tumor (DSRCT). The regimen is designed to exploit the synergistic effects of DNA damage, topoisomerase inhibition, and angiogenesis blockade. While generally reported to be tolerable with manageable hematologic and gastrointestinal toxicities, its efficacy has been moderate, and it is not a single branded product developed by a single company.
- Other names
- bevacizumab + irinotecan + temozolomidebevacizumab + temozolomide + irinotecanBIT regimenirinotecan + bevacizumab + temozolomideirinotecan + temozolomide + bevacizumabITB regimenTBI regimentemozolomide + irinotecan + bevacizumab
02
Targets
Beyond the preview
Go deeper on temozolomide + bevacizumab + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on temozolomide + bevacizumab + irinotecan.